Vion Pharmaceuticals Receives Response From FDA on Special Protocol Assessment for Onrigin(TM)

NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced today that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment ("SPA") for its oncology therapeutic Onrigin™ (laromustin

http://digg.com/u1OPYu